Navamedic launches new generic drug

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced the launch of a new generic pharmaceutical product. The new product will be introduced across Navamedic's key markets in the Nordic and Benelux regions.

Navamedic has been building up its portfolio of generic drugs since 2011 and expects to become a significant provider of generic drugs in the Nordic and Benelux markets over the next few years. The most recent addition to the Company's range of generic drugs is Levetiracetam Aspen, which is used in the treatment of patients suffering from epilepsy. Levetiracetam  Aspen can replace UCB's original drug Keppra.

Navamedic expects to launch additional generic drugs throughout 2013. The Company has a strong pipeline of candidates currently under review by medicines authorities.

For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.



Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).


This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)